

CURRICULUM VITAE

D. Eric Bolster, MD, CPI

BUSINESS ADDRESS

Palmetto Clinical Research
Investigator 1993-Present
1516 Old Trolley Rd., Ste. 100
Summerville, SC 29485
Phone: 843.851.7098 Fax: 843.851.0394

Oakbrook Internal Medicine
Private Practice 1993-Present
1516 Old Trolley Rd., Ste. 101, Summerville, SC 29485

HOSPITAL AFFILIATIONS

Trident Regional Medical Center
Charleston, SC

Summerville Medical Center
Summerville, SC 29485

LICENSURE

South Carolina
Medical License Number: MMD.16913 1993-Present
Virginia 1989-1992

CERTIFICATION

Board Certification
Internal Medicine 1991-Present

Association of Clinical Research Professionals
Certified Principal Investigator 2019-2021

Good Clinical Practice Training 2019

EDUCATION

Duke University School of Medicine, Durham, NC
Medical Doctor 1984-1988

The University of North Carolina, Chapel Hill, NC
Bachelor of Arts, Chemistry 1980-1984

PROFESSIONAL TRAINING

Naval Hospital, Portsmouth, VA
Resident, Internal Medicine 1989-1991

Naval Hospital, Portsmouth, VA
Internship, Internal Medicine 1988-1989

POSITIONS/TITLES

Medical University of South Carolina College of Medicine, Charleston, SC
Clinical Assistant Professor of Medicine 1992-1994

Naval Hospital, Charleston, SC
Staff Internist 1989-1991
Internal Medicine Department & Family Residency Program



9/12/19

RESEARCH EXPERIENCE

SEE ATTACHMENT

HONORS & AWARDS

Phi Eta Sigma Freshman Honor Society	1981
Alpha Epsilon Delta, Premedical Honor Society	1982 – 1984
Phi Beta Kappa Honor Society	1983
Health Professions Scholarship Program, US Navy	1984
Alpha Omega Alpha Honor Society	1987
Hewlett Packard Medical Graduate Award	1988
Aequanimitas Award	1991
Most Outstanding Senior Resident	1991
Best Clinical Instructor in Internal Medicine	1992
Best Clinical Instructor in Internal Medicine	1993

PUBLICATIONS

- R. Yee, K. Brown, D. Bolster, and H. Strauss
Relationship between ionic perturbations and electrophysiologic changes in canine Purkinje fiber model of ischemia and reperfusion.
J Clin Invest, 82:22-233 1988
- D. Eric Bolster, William E. Hatfield, and Leo Walter Haar
Exchange coupling in di-u-hydroxo-bis (S) alaninato Chromium (III), trihydrate.
Transition Metal Chemistry, 10:161-164 1985
- Michael, Megnamisi-Belcombe, D. Eric Bolster, Phirtu Singh, and William E. Hatfield
Catena-dichloro-(dipheny ethanedione) copper (II), a new one dimensional s=2 Heisenberg chain with a novel zig-zag structure.
Inorganic Chemistry, 23(17): 2578-2582 1984
- D. Eric Bolster, Phillip Gutlich, William E. Hatfield
Exchange coupling in tris (u-hydroxo)bis [(1,2,7-trimethyl-1, 4, 7-triazacyclononane) chromium(III)] triperchlorate trihydrate.
Inorganic Chemistry, 22(12): 1725-1729 1983

POSTER PRESENTATIONS

- The effect of one hour noise exposure on cochlear blood flow.*
Presented at the Association for Research in Otolaryngology Meeting, February 7, 1984 1984

MEMBERSHIPS

Association of Clinical Research Professionals

Clinical Trial Experience: D. Eric Bolster, MD

1)	Sponsor	Indication	From	To	Role
2)	Glaxo-Wellcome	Migraine	Sep 1994	Mar 1996	Sub-I
3)	Pharmaco LSR	Inpatient Community acquired pneumonia	Jan 1995	Dec 1996	Sub-I
4)	Parke Davis/Kendle	Congestive Heart Failure	Jan 1995	Dec 1995	Sub-I
5)	Baker Norton	Acute Ischemic Stroke	Apr 1996	Nov 1997	Sub-I
6)	Bristol Myers Squibb	Mild to Moderate HTN	Oct 1996	Apr 1997	Sub-I
7)	Searle/Parexel	HTN with Cardiovascular endpoints	Oct 1996	Dec 1998	Sub-I
8)	Bayer	Acute Exacerbations of Chronic Bronchitis	Oct 1996	May 1998	Sub-I
9)	Bayer	Community Acquired Pneumonia	Nov 1996	May 1998	Sub-I
10)	Janssen/ClinTrials	Acute Migraine	Jan 1997	Apr 1997	Sub-I
11)	Janssen/ClinTrials	Migraine	Mar 1997	Jun 1997	Sub-I
12)	Pfizer/PPD Pharmaco	Acute Sinusitis	Mar 1997	Sep 1997	PI
13)	SCIOS	Decompensated CHF	Apr 1997	Jul 1997	PI
14)	Bristol Myers Squibb	Mild to Moderate HTN	Jul 1997	Oct 1997	Sub-I
15)	HMR/Quintiles	Patients at risk of myocardial necrosis due to ACS	Aug 1997	Jul 1998	Sub-i
16)	Bristol Myers Squibb	Hypertension	Sep 1997	Dec 1997	Sub-I
17)	Parke-Davis & Pfizer	Hypercholesterolemia	Oct 1997	Jan 1998	Sub-I
18)	Glaxo Wellcome/ ClinTrials	Irritable Bowel Syndrome	Jan 1998	Aug 1998	PI
19)	Zeneca	Acute Migraine	Mar 1998	Jun 1998	PI
20)	Ortho-McNeil	Inpatient Serious Community Acquired Pneumonia	May 1998	Jan 2000	Sub-I
21)	Glaxo	Acute Bacterial Exacerbation of Chronic Bronchitis	Jun 1998	Mar 1999	Sub-I
22)	Glaxo	Community Acquired Pneumonia	Jun 1998	Mar 1999	PI
23)	SCIOS	Symptomatic, Decompensated CHF	Aug 1998	Dec 1998	PI
24)	Bristol Myers Squibb	Mild to Moderate HTN	Aug 1998	Mar 1999	PI
25)	Boehringer Ingelheim	Benign Prostatic Hypertrophy	Sep 1998	May 1999	Sub-I
26)	PPD/Pharmaco	Acute Maxillary Sinusitis	Oct 1998	Dec 1998	PI
27)	SmithKline Beecham	Systolic Hypertension	Nov 1998	Mar 1999	Sub-I
28)	SmithKline Beecham	Community Acquired Pneumonia	Nov 1998	Jun 1999	Sub-I
29)	SmithKline Beecham	Acute Exacerbation of Chronic Bronchitis	Nov 1998	Apr 1999	PI
30)	SmithKline Beecham	Pyelonephritis or Complicated UTI	Nov 1998	May 1999	Sub-I
31)	Glaxo	Irritable Bowel Syndrome	Dec 1998	May 1999	PI
32)	Pfizer	Community Acquired Pneumonia or Acute Exacerbation of COPD	Dec 1998	Mar 2000	Sub-I
33)	Novartis	Essential Hypertension	Mar 1999	Nov 1999	Sub-I
34)	Merck	Hypercholesterolemia	Mar 1999	Aug 1999	Sub-I

Clinical Trial Experience: D. Eric Bolster, MD

35)	Glaxo	Influenza	Mar 1999	Apr 1999	Sub-I
36)	SmithKline Beecham	Type II Diabetes Mellitus	Aug 1999	Feb 2000	Sub-I
37)	Novo Nordisk	Insulin Dependent Type II Diabetes Mellitus	Sep 1999	Feb 1999	Sub-I
38)	Novo Nordisk	Type II Diabetes	Sep 1999	Mar 2000	Sub-I
39)	Bristol Myers Squibb	Acute Maxillary Sinusitis	Sep 1999	Dec 1999	PI
40)	Abbott	Community Acquired Pneumonia	Nov 1999	May 2000	PI
41)	SmithKline Beecham	Acute Exacerbation of Chronic Bronchitis	Nov 1999	Feb 2000	PI
42)	SmithKline Beecham	Bacterial Community Acquired Pneumonia	Dec 1999	Jun 2002	Sub-I
43)	Bristol Myers Squibb	Acute Stroke	Dec 1999	Nov 2000	PI
44)	Glaxo Wellcome	Irritable Bowel Syndrome	Dec 1999	Jul 2000	PI
45)	Glaxo Wellcome	Irritable Bowel Syndrome	Dec 1999	Jun 2000	PI
46)	Bayer	Inpatient Community Acquired Pneumonia	Dec 1999	May 2000	Sub-I
47)	SmithKline Beecham	Influenza	Jan 2000	Mar 2000	Sub-I
48)	Novo Nordisk	Type II Diabetes Mellitus	Feb 2000	Dec 2000	Sub-I
49)	Merck	Osteoarthritis	Apr 2000	Aug 2000	Sub-I
50)	SmithKline Beecham	Hyperlipidemia	May 2000	Aug 2000	Sub-I
51)	Bristol Myers Squibb	C-Reactive Protein	Jun 2000	Jun 2000	Sub-I
52)	Glaxo Wellcome	Asthma	Jun 2000	Aug 2000	Sub-I
53)	Glaxo Wellcome	Irritable Bowel Syndrome	Jul 2000	Oct 2000	PI
54)	SmithKline Beecham	Acute Exacerbations of Chronic Bronchitis	Oct 2000	Jan 2001	PI
55)	Bristol Myers Squibb	Hypertension	Oct 2000	Jan 2001	Sub-I
56)	Bayer	Community Acquired Pneumonia	Nov 2000	Jun 2002	Sub-I
57)	Abbott Laboratories	Community Acquired Pneumonia	Dec 2000	Dec 2001	PI
58)	Glaxo SmithKline	Inpatient Community Acquired Pneumonia	Dec 2000	Jan 2000	Sub-I
59)	Pfizer	Acute Bacterial Sinusitis	Mar 2001	Dec 2001	Sub-I
60)	Glaxo SmithKline	Pneumonia	Apr 2001	Feb 2002	Sub-I
61)	Astra Zeneca	Hypercholesterolemia	May 2001	Dec 2001	PI
62)	Astra Zeneca	Hypercholesterolemia	May 2001	May 2002	PI
63)	Bayer	Pneumonia	Jun 2001	Feb 2002	Sub-I
64)	Bayer	Complicated UTI or Acute Uncomplicated Pyelonephritis	Jul 2001	Jun 2002	Sub-I
65)	Bayer	Acute Exacerbation of Chronic Bronchitis	Jul 2001	Apr 2002	Sub-I
66)	Glaxo SmithKline	Type II Diabetics with HTN	Jul 2001	Jul 2003	Sub-I
67)	Bayer	Urinary Tract Infection	Sep 2001	Jan 2002	Sub-I
68)	Bristol Myers Squibb	Type II Diabetes	Nov 2001	Jun 2006	PI
69)	Glaxo SmithKline	Acute Exacerbations of Chronic Bronchitis	Dec 2001	Apr 2002	Sub-I
70)	Astra Zeneca	Hypercholesterolemia	Feb 2002	May 2003	PI
71)	Pfizer	Acute Exacerbations of Chronic Bronchitis	Mar 2002	Dec 2002	Sub-I
72)	Novartis	Osteoarthritis	Apr 2002	Dec 2002	Sub-I

Clinical Trial Experience: D. Eric Bolster, MD

73)	Merck	Combined Hyperlipidemia	Jun 2002	Feb 2003	Sub-I
74)	Glaxo SmithKline	Irritable Bowe Syndrome	Jul 2002	Oct 2002	PI
75)	Astra Zeneca	Type II Diabetes	Oct 2002	Jan 2003	Sub-I
76)	Abbott	Pneumonia	Oct 2002	Nov 2002	PI
77)	Glaxo SmithKline	Type II Diabetes	Mar 2003	Oct 2003	PI
78)	Bristol Myers Squibb	Type II Diabetes	Jun 2003	Oct 2003	PI
79)	Bristol Myers Squibb	Type II Diabetes	Jun 2003	Oct 2003	PI
80)	Astra Zeneca	Hypercholesterolemia	Aug 2003	Jan 2004	PI
81)	Bayer	Urinary Tract Infections	Aug 2003	Oct 2003	Sub-I
82)	Novartis	Hypertension	Sep 2003	Mar 2004	Sub-I
83)	Pfizer	Pneumonia	Oct 2003	Feb 2004	Sub-I
84)	Glaxo SmithKline	Irritable Bowel Syndrome	Oct 2003	Sep 2005	PI
85)	Bayer	Pneumonia	Oct 2003	Mar 2004	Sub-I
86)	Bristol Myers Squibb	Severe Hypertension	Oct 2003	Mar 2004	PI
87)	Bristol Myers Squibb	Moderate Hypertension	Oct 2003	Dec 2004	PI
88)	Merck	Osteoporosis	Dec 2003	Mar 2004	Sub-I
89)	Wyeth Research	Inpatient Pneumonia	Jan 2004	Jun 2005	Sub-I
90)	Peninsula Pharma	Lower UTI or Pyelonephritis	Aug 2004	Feb 2006	Sub-I
91)	Pfizer	Osteoarthritis	Sep 2004	Jan 2005	Sub-I
92)	Pozen	Migraine	Sep 2004	Dec 2004	Sub-I
93)	Novartis	Essential Hypertension	Mar 2005	July 2005	Sub-I
94)	Pfizer	Fibromyalgia	Nov 2005	Apr 2006	Sub-I
95)	Pfizer	Fibromyalgia	Nov 2005	Jul 2006	Sub-I
96)	Glaxo SmithKline	Acute Exacerbation of COPD	Dec 2005	Jul 2006	PI
97)	Ortho McNeal	Complicated UTI/Acute Pyelonephritis	Dec 2005	Mar 2006	Sub-I
98)	Novartis	Hypertension	Dec 2006	Jul 2006	PI
99)	Novartis	Hypertension	Jan 2006	Jun 2006	Sub-I
100)	Aventis	Respiratory Tract Infections	Jan 2006	Sep 2006	Sub-I
101)	Pfizer	Osteoarthritis	Feb 2006	Jul 2006	Sub-I
102)	Abbott	Mixed Dyslipidemia	Apr 2006	Jul 2006	Sub-I
103)	Boehringer Ingelheim	Atrial Fibrillation	Apr 2006	Dec 2007	PI
104)	Advanced Life Science	Pneumonia	May 2006	Sep 2007	PI
105)	Wyeth	Fibromyalgia	Jul 2006	Jun 2007	Sub-I
106)	Speedel	Diabetic Nephropathy	Sep 2006	Dec 2006	Sub-I
107)	Abbott	Mixed Dyslipidemia	Sep 2006	Dec 2007	Sub-I
108)	Wyeth	Fibromyalgia	Jan 2007	Dec 2007	Sub-I
109)	Pfizer	Osteoarthritis/ Rheumatoid Arthritis	Jan 2007	Aug 2016	Sub-I
110)	Microbia	Chronic Constipation	Jan 2007	Nov 2007	PI
111)	Novartis	Type II Diabetes	Jan 2007	Aug 2007	PI
112)	Pfizer	Osteoarthritis	Mar 2007	Jun 2007	Sub-I
113)	Microbia	Irritable Bowel Syndrome	Apr 2007	Aug 2007	PI
114)	Merck	Hypercholesterolemia/ Mixed Dyslipidemia	Aug 2007	Mar 2008	Sub-I
115)	Boehringer Ingelheim	Venous thromboembolism	Aug 2007	Jan 2010	PI
116)	Boehringer Ingelheim	Acute symptomatic venous thromboembolism	Aug 2007	Jan 2010	PI

Clinical Trial Experience: D. Eric Bolster, MD

117)	Bristol Myers Squibb	Type II Diabetes	Sep 2007	Apr 2008	PI
118)	Merck	Type II Diabetes	Oct 2007	Jun 2008	Sub-I
119)	Boehringer Ingelheim	Venous Thromboembolism	Feb 2008	Dec 2008	PI
120)	Boehringer Ingelheim	Venous Thromboembolism	Feb 2008	Dec 2008	PI
121)	Merck	Hypertension	Apr 2008	Jun 2008	PI
122)	Abbott	Atherogenic Dyslipidemia	Apr 2008	Jun 2008	Sub-I
123)	Pfizer	Overactive Bladder	Apr 2008	Jun 2009	Sub-I
124)	Cogentus	Gastrointestinal Events	Apr 2008	Nov 2008	Sub-I
125)	Bristol Myers Squibb	Type II Diabetes/ Moderate Renal Impairment	Aug 2008	Dec 2009	PI
126)	Boehringer Ingelheim	Acute symptomatic venous thromboembolism	Aug 2008	Jan 2010	PI
127)	Bristol Myers Squibb	Type 2 Diabetes and Renal Impairment	Aug 2008	Aug 2010	PI
128)	Bristol Myers Squibb	Type II Diabetes	Aug 2008	Dec 2008	PI
129)	Merck	Hypercholesterolemia/ Mixed Hyperlipidemia	Aug 2008	Mar 2009	Sub-I
130)	Boehringer Ingelheim	Venous Thromboembolism	Aug 2008	Nov 2009	PI
131)	Ironwood	Chronic Constipation	Sep 2008	May 2010	PI
132)	Ironwood	Chronic Constipation/IBS	Sep 2008	Jun 2011	PI
133)	Boehringer Ingelheim	Atrial Fibrillation	Oct 2008	Jan 2010	PI
134)	Daiichi Sanyko	Atrial Fibrillation	Jan 2009	Nov 2010	Sub-I
135)	Ironwood	Irritable Bowel Syndrome/Constipation	Jun 2009	May 2010	PI
136)	Ironwood	Irritable Bowel Syndrome/Constipation	Jun 2009	May 2010	PI
137)	Ironwood	Irritable Bowel Syndrome	Aug 2009	Sep 2009	PI
138)	Abbott	Chronic Kidney Disease	Nov 2009	Jun 2010	PI
139)	Novartis	HTN/Type II Diabetes	Aug 2009	Aug 2011	Sub-I
140)	Ironwood	Chronic Constipation	Oct 2008	Apr 2009	PI
141)	Abbott	Dyslipidemia	Jan 2010	Aug 2010	PI
142)	Bristol Myers Squibb	HTN/Type II Diabetes	Jun 2010	Dec 2010	PI
143)	Bristol Myers Squibb	HTN/Type II Diabetes	Oct 2010	Dec 2010	PI
144)	Pfizer	Deep Vein Thrombosis/ Pulmonary Embolism	Dec 2010	Jul 2011	PI
145)	Novartis	HTN/Type II Diabetes	Dec 2010	Mar 2012	Sub-I
146)	Pfizer	Deep Vein Thrombosis/ Pulmonary Embolism	Dec 2010	Jul 2012	PI
147)	Pozen	Aspirin-Associated Ulcers	Mar 2011	Jun 2011	PI
148)	Merck	Overactive bladder	May 2011	Apr 2012	PI
149)	Forest	HTN	Sep 2011	Dec 2011	PI
150)	Boston Scientific	Congestive Heart Failure Devise	2011	2012	Sub-I
151)	Forest	HTN	Jan 2012	Oct 2012	PI
152)	Merck	Type II Diabetes	Feb 2012	Apr 2012	PI
153)	Forest	Diabetic Peripheral Neuropathic Pain	Apr 2012	Oct 2012	PI
154)	Sanofi	Hypercholesterolemia	Apr 2012	Apr 2013	PI

Clinical Trial Experience: D. Eric Bolster, MD

155)	Furiex	Irritable Bowel Syndrome	Jul 2012	Jun 2013	PI
156)	Pfizer	Hypercholesterolemia	Sept 2012	Nov 2012	PI
157)	Sanofi	Hypercholesterolemia	Nov 2012	May 2012	PI
158)	Cempra	Pneumonia	Dec 2012	Jan 2015	PI
159)	Repros	Endometriosis	Sep 2012	Jan 2017	PI
160)	Synergy	IBS with Constipation	Apr 2013	May 2014	PI
161)	Mylan	Herpes Simplex	Jun 2013	Apr 2014	PI
162)	Regeneron	Hypercholesterolemia with Cardiovascular Events	Jul 2013	Aug 2013	PI
163)	Regeneron	Hypercholesterolemia with Cardiovascular Events	Jul 2013	Aug 2013	PI
164)	Regeneron	Statin Intolerant Hypercholesterolemia	Jul 2013	Jan 2017	PI
165)	Merck	Metformin Intolerant Type II Diabetes Mellitus	Jul 2013	Jul 2014	PI
166)	Forest	COPD	Sep 2013	Nov 2017	PI
167)	Merck	Type II Diabetes Mellitus w/ Cardiovascular Disease	Jan 2013	Oct 2016	PI
168)	Astellas	Overactive Bladder	Jan 2014	Feb 2016	PI
169)	Astellas	Overactive Bladder	Jul 2014	Nov 2016	PI
170)	Esperion	Hypercholesterolemia/Lipidemia	Jul 2014	Feb 2015	PI
171)	Shionogi	Opioid Induced Constipation	Dec 2013	Mar 2016	PI
172)	Pfizer	Cholesterol	Nov 2013	Aug 2016	PI
173)	Sanofi	Hypercholesterolemia	Mar 2014	Sep 2015	PI
174)	AstraZeneca	Asthma	Jun 2014	Jan 2016	PI
175)	Mariner	Deep Vein Thrombosis	Jun 2014	Nov 2016	Sub-I
176)	Novo Nordisk	Diabetes Mellitus Type I	Jan 2014	Aug 2015	PI
177)	Pfizer	Cholesterol	Jun 2014	Mar 2016	PI
178)	Cymabay	Gout	Jun 2014	Feb 2015	PI
179)	AstraZeneca	Type II Diabetes	Jan 2015	Mar 2018	Sub-I
180)	Merck/Pfizer	Type II Diabetes	Jan 2015	Oct 2017	PI
181)	Repros	Uterine Fibroid	Mar 2015	Dec 2016	PI
182)	Daiichi Sankyo	Fibromyalgia	Mar 2015	Oct 2017	Sub-I
183)	Pfizer	Hypercholesterolemia/Lipidemia	May 2015	Mar 2016	PI
184)	Bayer Health Care	Contraception	Jun 2015	Nov 2016	Sub-I
185)	Arisaph	Cholesterol	Oct 2015	Nov 2016	PI
186)	Catabasis	Cholesterol	Oct 2015	Jun 2016	PI
187)	Sanofi	DM II Toujeo	Nov 2015	Dec 2018	Sub-I
188)	Elcelyx	DM II Metformin Intolerant	Nov 2015	Nov 2016	PI
189)	Egalet	Chronic pain	Jan 2016	Sep 2017	Sub-I
190)	Novo Nordisk	DM II	Feb 2016	Jul 2018	PI
191)	Sanofi	High Cholesterol w/ DM II	Mar 2016	Jul 2017	PI
192)	Cempra	Acute Bacterial Skin Infection	Jun 2016	Mar 2017	PI
193)	Shionogi	Vaginal Dryness	Jul 2016	Nov 2017	Sub-I
194)	Braintree	Opioid Induced Constipation	Jul 2016	Jul 2017	PI
195)	Novo Nordisk	DM II	Jul 2016	Jul 2018	PI
196)	Ligand	DM II on Metformin	Jul 2016	Jul 2017	PI
197)	Novo Nordisk	DM II on Insulin	Feb 2017	Nov 2018	PI
198)	Amgen	Hyperlipidemia	Mar 2017	ONGOING	Sub-I
199)	Esperion	Hyperlipidemia	Mar 2017	May 2018	Sub-I
200)	Novartis	Weight Loss	Jun 2017	Nov 2018	PI

Clinical Trial Experience: D. Eric Bolster, MD

201)	Regeneron	Hyperlipidemia	Apr 2017	ONGOING	PI
202)	AbbVie	Endometriosis	Jun 2017	ONGOING	Sub-I
203)	Bayer	Essure vs. Tubaligation	Jun 2017	ONGOING	Sub-I
204)	Novartis	Cardiovascular	Oct 2017	ONGOING	PI
205)	Esperion	Hyperlipidemia	Dec 2017	ONGOING	Sub-I
206)	Sanofi	DM II PSK9 Auto Injector	Dec 2017	Oct 2018	PI
207)	Urovant	OAB	Feb 2018	Mar2019	PI
208)	Urovant	OAB	Jul 2018	ONGOING	PI
209)	Acasti	Severe Hypertriglyceridemia	Jan 2018	ONGOING	Sub-I
210)	AbbVie	Testosterone Replacement Therapy	May 2018	ONGOING	PI
211)	AbbVie	Endometriosis-Bone Density	Jul 2018	Apr 2019	Sub-I
212)	Merck	Endometriosis Pain	Jul 2018	ONGOING	Sub-I
213)	Corcept	Cushing's Disease	Nov 2018	ONGOING	Sub-I
214)	Aribio	Alzheimer's mild - moderate	Nov 2018	ONGOING	Sub-I
215)	Regeneron	Hyperlipidemia	Jan 2019	ONGOING	PI
216)	Kowa	Hypertriglyceridemia	Mar 2019	ONGOING	Sub-I
217)	Pfizer	DM II w/ CV	Mar 2019	ONGOING	PI
218)	Astellas	Vasomotor Symptoms	Jul 2019	ONGOING	Sub-I
219)	Astellas	Vasomotor Symptoms	Jul 2019	ONGOING	Sub-I
220)	Amgen	CV outcome	Jul 2019	ONGOING	Sub-I
221)	Merck	HCMV vaccine	Jul 2019	ONGOING	Sub-I


 9/12/19